A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia

William L Pridgen, Carol Duffy, Judy F Gendreau, R Michael Gendreau, William L Pridgen, Carol Duffy, Judy F Gendreau, R Michael Gendreau

Abstract

Objective: Infections and other stressors have been implicated in the development of fibromyalgia. We hypothesized that these stressors could result in recurrent reactivations of latent herpes virus infections, which could lead to the development of fibromyalgia. This study evaluated a famciclovir + celecoxib drug combination (IMC-1), active against suspected herpes virus reactivation and infection, for the treatment of fibromyalgia.

Methods: A total of 143 fibromyalgia patients were enrolled at 12 sites in a 16-week, double-blinded, placebo-controlled proof-of-concept trial. Randomized patients received either IMC-1 or placebo in a 1:1 ratio. Outcome measures included a 24-hour recall pain Numerical Rating Scale, the Revised Fibromyalgia Impact Questionnaire (FIQ-R), the Patient's Global Impression of Change (PGIC) questionnaire, the Multidimensional Fatigue Inventory, the NIH Patient-Reported Outcomes Measurement Information System (PROMIS), and the Beck Depression Inventory-II conducted at baseline and weeks 6, 12, and 16 of the study.

Results: A significant decrease in fibromyalgia-related pain was observed for patients on IMC-1 treatment versus placebo. PGIC response rates were significantly improved with IMC-1 treatment. Overall, patient self-reported functioning, as measured by the FIQ-R, was significantly improved. Fatigue was also significantly improved as measured by the PROMIS fatigue inventory. The safety profile was encouraging. Despite the celecoxib component of IMC-1, gastrointestinal and nervous system treatment emergent adverse events were reported less frequently in the IMC-1 group, and study completion rates favored IMC-1 treatment.

Conclusion: IMC-1 was efficacious and safe in treating symptoms of fibromyalgia, supporting the hypothesis that herpes virus infections may contribute to this syndrome. Improved retention rates, decreased adverse event rates, and evidence of efficacy on a broad spectrum of outcome measures are suggestive that IMC-1 may represent an effective, novel treatment for fibromyalgia.

Keywords: antiviral; celecoxib; famciclovir; fibromyalgia; herpes virus.

Conflict of interest statement

Disclosure This study was funded by Innovative Med Concepts, LLC (IMC). William L Pridgen is the founder and CEO of IMC and is a shareholder in IMC. Carol Duffy received research support from IMC in the form of a Sponsored Research Agreement between the University of Alabama and IMC. Judy F Gendreau and R Michael Gendreau are paid consultants for IMC. The authors would like to disclose that this research was presented at the American College of Rheumatology 78th Annual Meeting/Association of Rheumatology Health Professionals 49th Annual Meeting November 14–19, 2014 Boston, MA. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Distribution of patients screened and randomized to placebo or IMC-1 for the 16-week trial.

References

    1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19–28.
    1. Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken) 65(5):786–792.
    1. McBeth J, Jones K. Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007;21(3):403–425.
    1. Staud R. Fibromyalgia pain: do we know the source? Curr Opin Rheumatol. 2004;16(2):157–163.
    1. Buskila D, Atzeni F, Sarzi-Puttini P. Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun Rev. 2008;8(1):41–43.
    1. Wolfe F, Anderson J, Harkness D, et al. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum. 1997;40(9):1571–1579.
    1. Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J, et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain. 1996;65(2–3):221–225.
    1. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum. 1991;34(5):552–560.
    1. Buskila D. Drug therapy. Baillieres Best Pract Res Clin Rheumatol. 1999;13(3):479–485.
    1. Leventhal LJ. Management of fibromyalgia. Ann Intern Med. 1999;131(11):850–858.
    1. Rao SG, Bennett RM. Pharmacological therapies in fibromyalgia. Best Pract Res Clin Rheumatol. 2003;17(4):611–627.
    1. Hill JM, Lukiw WJ, Gebhardt BM, et al. Gene expression analyzed by microarrays in HSV-1 latent mouse trigeminal ganglion following heat stress. Virus Genes. 2001;23(3):273–280.
    1. Ray N, Enquist LW. Transcriptional response of a common permissive cell type to infection by two diverse alphaherpesviruses. J Virol. 2004;78(7):3489–3501.
    1. Liu Y, Li S, Wang Z. The role of cyclooxygenase in multiplication and reactivation of HSV-1 in vestibular ganglion neurons. Scientific World Journal. 2014;2014:912640.
    1. Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol. 1969;4(2):203–214.
    1. Newton AA. Inhibitors of prostaglandin synthesis as inhibitors of herpes simplex virus replication. Adv Ophthalmol. 1979;38:58–63.
    1. Harbour DA, Blyth WA, Hill TJ. Prostanglandins enhance spread of herpes simplex virus in cell cultures. J Gen Virol. 1978;41(1):87–95.
    1. Chang TW. Prostaglandin synthetase inhibitors in primary herpes infections. J Infect. 1980;2(4):374–375.
    1. Wachsman M, Aurelian L, Burnett JW. The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections. Br J Dermatol. 1990;123(3):375–380.
    1. Higaki S, Watanabe K, Itahashi M, Shimomura Y. Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model. Curr Eye Res. 2009;34(3):171–176.
    1. Gebhardt BM, Varnell ED, Kaufman HE. Inhibition of cyclooxygenase 2 synthesis suppresses Herpes simplex virus type 1 reactivation. J Ocul Pharmacol Ther. 2005;21(2):114–120.
    1. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997;4(3):134–153.
    1. Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antivir Chem Chemoth. 1993;4:67–84.
    1. Kendall SA, Schaadt ML, Graff LB, et al. No effect of antiviral (valacyclovir) treatment in fibromyalgia: a double blind, randomized study. J Rheumatol. 2004;31(4):783–784.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren